Bausch Health falls after RBC Capital Markets lowers PT

Bausch Health Companies

07/04/2025 16:36

** U.S.-listed shares of eye care firm Bausch Health BHC.TO down 4.2% at $5.06

** Brokerage RBC Capital Markets cuts PT to $8.5 from $9 ahead of Q1 results, maintains "sector perform" rating

** The new price target represents a 59.5% upside to the stock's last close

 ** Company is set to
share Q1 results
 on April 30 - brokerage

** RBC estimates Q1 revenue of $2.24 billion on "broader macroeconomic uncertainty currently"

** "If a sale of BLCO were to take place, we anticipate it would most likely happen in the 2026-2027 time frame" - RBC

** Bausch + Lomb BLCO.TO said in December 2024 it is exploring a potential sale among other options, in a move that would help Canadian parent Bausch Health BHC.TO exit the eye-care company

** Brokerage says BLCO's dry-eye treatment, Miebo, will turn profitable in 2026

** Up to Friday's close, stock had fallen 35.4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))